Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Investor in connection with Swedish Orphan Biovitrum’s rights issue
Mandate

Vinge advises Investor in connection with Swedish Orphan Biovitrum’s rights issue

April 01, 2011

Vinge is advising Investor AB in connection with Swedish Orphan Biovitrum AB’s (SOBI) rights issue for a total of approximately SEK 600 million subject to pre-emption rights of the existing shareholders. SOBI is listed on NASDAQ OMX Stockholm. Investor AB and Bo Jesper Hansen (SOBI’s chairman) have undertaken to subscribe for their share of the rights issue and the issue has been underwritten by Carnegie and Handelsbanken. As a consequence thereof, Investor has obtained the requisite dispensation from the Swedish Securities Council.

Vinge’s team advising Investor consists of Olle Sandersson, Pontus Enquist and Jesper Schönbeck.

Related

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

 Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025